Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Isoniazid Loaded PCL-PEG Copolymer Nanoparticles for Sustained Release Application

Author(s): Alpana Kulkarni* and Priya Betai

Volume 18, Issue 3, 2023

Published on: 04 April, 2023

Page: [221 - 238] Pages: 18

DOI: 10.2174/2772434418666230228121730

Price: $65

Abstract

Background: Tuberculosis (TB) is still a major cause of death worldwide, despite possibly curable therapies. Neurotoxicity, optic neuritis, and severe liver damage are side effects of isoniazid, a powerful first-line anti-TB drug.

Objective: We investigated the use of PCL-PEG copolymer to sustain the release of isoniazid to reduce its adverse effects.

Methods: In the present work, PCL-PEG copolymer was synthesized and characterized. Isoniazid-loaded nanoparticles (Inp) were prepared using a PCL-PEG copolymer. Furthermore, a 23 half factorial design was employed for the optimization of drug and emulsifier concentration in Inp. Full characterization of the nanoparticles was performed in terms of drug loading, entrapment efficiency, particle size, zeta potential, and in vitro drug release. The morphology, FTIR, DSC, and PXRD evaluation of the optimized Batch Inp F13 were studied. Stability was evaluated by storing the freeze-dried Inp F13 at various temperatures.

Results: The entrapment efficiency and drug loading of nanoparticles prepared by double emulsion solvent evaporation were found to be the highest. The release study revealed that all batches of nanoparticles exhibited sustained drug release (60.26 - 88.59%) for 5 days. The cytotoxicity study conducted on Mycobacterium tuberculosis revealed a gradual release of isoniazid from Inp, reaching the maximum (on the 15th day) compared to plain isoniazid (on the 4th day). At 0.8 μg/mL concentration, the inhibitory activity of Inp F13 was maintained for 15 days, indicating sustained release of isoniazid.

Conclusion: The nanoparticles having PCL:PEG in a 95:5 ratio, with 0.5% PVA and initial drug loading of 3 mg, produced the optimum batch. Isoniazid-loaded PCL-PEG nanoparticles allowed controlled (sustained) release of isoniazid.

« Previous Next »
Graphical Abstract

[1]
Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA. pH-responsive isoniazid-loaded nanoparticles markedly improve tuberculosis treatment in mice. Small 2015; 1(38): 5066-78.
[2]
Nair R, Vishnu Priya K, Arun Kumar KS, Badivaddin TM, Sevukarajan M. Formulation and evaluation of solid lipid nanoparticles of water-soluble drug: Isoniazid. J Pharm Sci Res 2011; 3(5): 1256-64.
[3]
Ang CW, Tan L, Qu Z, et al. Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles ACS. Biomater Sci Eng 2021; 8(10): 4196-206.
[PMID: 34464089]
[4]
Zargarnezhad S, Gholami A, Khoshneviszadeh M, Abootalebi SN, Ghasemi Y. Antimicrobial activity of isoniazid in conjugation with surface-modified magnetic nanoparticles against Mycobacterium tuberculosis and nonmycobacterial microorganisms. Hindawi J Nanomater 2020; 2020: 9.
[5]
Junise V, Saraswathi R. Development and characterization of inhaled chitosan nanoparticles loaded with isoniazid. J Pharm Technol Res Manage 2014; 2(2): 159-70.
[6]
Sarmah M, Hussain A, Ramteke A, Maji TK. Isoniazid loaded gelatin-cellulose whiskers nanoparticles for controlled drug delivery applications. J Chem Sci 2016; 128(8): 1291-301.
[http://dx.doi.org/10.1007/s12039-016-1129-6]
[7]
Gilani K, Najafabadi AR, Darabi M, Barghi M, Rafiee-Tehrani M. Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols. Daru 2004; 12: 123-30.
[8]
Nasiruddin M, Neyaz Md. Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat 2017; 2017: 4920209.
[9]
Iqbal K, Abdalla SAO, Anwar A, et al. Isoniazid conjugated magnetic nanoparticles loaded with amphotericin b as a potent antiamoebic agent against Acanthamoeba castellanii. Antibiotics 2020; 9(5): 276.
[http://dx.doi.org/10.3390/antibiotics9050276] [PMID: 32466210]
[10]
Tazhbayev Y, Galiyeva A, Zhumagaliyeva T, Burkeyev M, Karimova B. Isoniazid-loaded albumin nanoparticles: Taguchi optimization method. Polymers 2021; 13(21): 3808.
[http://dx.doi.org/10.3390/polym13213808] [PMID: 34771365]
[11]
Lunn AM, Unnikrishnan M, Perrier S. Dual pH-responsive macrophage-targeted isoniazid glycoparticles for intracellular tuberculosis therapy. Biomacromolecules 2021; 22(9): 3756-68.
[http://dx.doi.org/10.1021/acs.biomac.1c00554] [PMID: 34339606]
[12]
Pi J, Shen L, Yang E, et al. Macrophage-targeted isoniazid-selenium nanoparticles promote antimicrobial immunity and synergize bactericidal destruction of Tuberculosis bacilli. Angew Chem Int Ed 2020; 59(8): 3226-34.
[http://dx.doi.org/10.1002/anie.201912122] [PMID: 31756258]
[13]
Kiliç G, Fernández-Bertólez N, Costa C, et al. The application, neurotoxicity, and related mechanism of iron oxide nanoparticles. neurotoxicity of nanomaterials and nanomedicine. New York: Academic Press 2017; pp. 127-50.
[http://dx.doi.org/10.1016/B978-0-12-804598-5.00006-4]
[14]
Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Varnamkhasti BS, Saboury AA. Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Biomed Pharmacother 2019; 109: 1100-11.
[http://dx.doi.org/10.1016/j.biopha.2018.10.167] [PMID: 30551360]
[15]
Bisht N, Phalswal P, Khanna PK. Selenium nanoparticles: A review on synthesis and biomedical applications. Mater Adv 2022; 3(3): 1415-31.
[http://dx.doi.org/10.1039/D1MA00639H]
[16]
Tanga S, Maji B. Recent trends in precision drug and gene delivery. Appl Nanomed 2022; 22(2): 429-35.
[17]
Sri VS, George M. In vitro anticancer and antitubercular activities of cellulose-magnetite nanocomposite synthesized using deep eutectic solvent as a dispersant. J Mater NanoSci 2021; 8(1): 1-10.
[18]
Boffito M, Sirianni P, Di Rienzo AM, Chiono V. Thermosensitive block copolymer hydrogels based on poly(ɛ-caprolactone) and polyethylene glycol for biomedical applications: State of the art and future perspectives. J Biomed Mater Res A 2015; 103(3): 1276-90.
[http://dx.doi.org/10.1002/jbm.a.35253] [PMID: 24912941]
[19]
Danafar H. Study of the composition of polycaprolactone/poly (ethylene glycol)/polycaprolactone copolymer and drug-to-polymer ratio on drug loading efficiency of curcumin to nanoparticles. Jundishapur J Nat Pharm Prod 2017; 12(1): e34179.
[20]
Hoang Thi TT, Pilkington EH, Nguyen DH, Lee JS, Park KD, Truong NP. The importance of poly(ethylene glycol) alternatives for overcoming peg immunogenicity in drug delivery and bioconjugation. Polymers 2020; 12(2): 298.
[http://dx.doi.org/10.3390/polym12020298] [PMID: 32024289]
[21]
Mahmoudi SM. Strategies for surface modification of gelatin-based nanoparticles. Colloids Surf B Biointerfaces 2019; 183: 110407.
[http://dx.doi.org/10.1016/j.colsurfb.2019.110407] [PMID: 31400613]
[22]
Singh U, Akhtar S, Mishra A, Sarkar D. A novel screening method based on menadione mediated rapid reduction of tetrazolium salt for testing of antimycobacterial agents. J Microbiol Methods 2011; 84(2): 202-7.
[http://dx.doi.org/10.1016/j.mimet.2010.11.013] [PMID: 21129420]
[23]
Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F, Nanoencapsulation I. Methods for preparation of drugloaded polymeric nanoparticles. Nanomedicine 2006; 2(1): 8-21.
[http://dx.doi.org/10.1016/j.nano.2005.12.003] [PMID: 17292111]
[24]
Feng R, Song Z, Zhai G. Preparation and in vivo pharmacokinetics of curcumin-loaded PCL-PEG-PCL triblock copolymeric nanoparticles. Int J Nanomedicine 2012; 7: 4089-98.
[http://dx.doi.org/10.2147/IJN.S33607] [PMID: 22888245]
[25]
Greene JP. Microstructure of polymers. automotive plastics and composites. Applied Science Publishers 2021; pp. 27-37.
[http://dx.doi.org/10.1016/B978-0-12-818008-2.00009-X]
[26]
Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27(1): 1-12.
[http://dx.doi.org/10.1007/BF02980037] [PMID: 14969330]
[27]
Cui Y, Jin R, Zhou Y, Yu M, Ling Y, Wang LQ. Crystallization enhanced thermal-sensitive hydrogels of PCL-PEG-PCL triblock copolymer for 3D printing. Biomed Mater 2021; 16(3): 035006.
[http://dx.doi.org/10.1088/1748-605X/abc38e] [PMID: 33086194]
[28]
Becker C, Dressman JB, Amidon GL, et al. Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J Pharm Sci 2007; 96(3): 522-31.
[http://dx.doi.org/10.1002/jps.20765] [PMID: 17117431]
[29]
Peltonen L, Aitta J, Hyvönen S, Karjalainen M, Hirvonen J. Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech 2004; 5(1): E16.
[PMID: 15198537]
[30]
Riess G. Micellization of block copolymers. Prog Polym Sci 2003; 28(7): 1107-70.
[http://dx.doi.org/10.1016/S0079-6700(03)00015-7]
[31]
Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 2004; 93(7): 1804-14.
[http://dx.doi.org/10.1002/jps.20094] [PMID: 15176068]
[32]
Nawaz T, Iqbal M, Khan BA, et al. Development and optimization of acriflavine-loaded polycaprolactone nanoparticles using box-behnken design for burn wound healing applications. Polymers 2021; 14(1): 101.
[http://dx.doi.org/10.3390/polym14010101] [PMID: 35012125]
[33]
Clogston JD, Patri AK. Zeta potential measurement. Methods Mol Biol 2011; 697: 63-70.
[http://dx.doi.org/10.1007/978-1-60327-198-1_6] [PMID: 21116954]
[34]
Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 2009; 136(1): 2-13.
[http://dx.doi.org/10.1016/j.jconrel.2008.12.018] [PMID: 19331856]
[35]
He X, Li L, Su H, et al. Poly(ethylene glycol)-blockpoly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery. Int J Nanomedicine 2015; 10(1): 1791-804.
[PMID: 25784805]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy